Our Faculty

Home » Our Faculty » R. Graham Barr

R. Graham Barr

Associate Professor of Epidemiology

and:
Florence Irving Associate Professor of Medicine, College of Physicians and Surgeons (home dept.)


Biography:
Dr. R. Graham Barr's research is primarily in respiratory epidemiology, relating to risk factors for asthma and chronic obstructive pulmonary disease (COPD). He has evaluated hormonal and analgesic risk factors for asthma and COPD in the Nurses' Health Study and is currently evaluating usage of over-the-counter analgesic drugs during asthma exacerbations. He is principal investigator (PI) of a longitudinal cohort study of fish oil intake and COPD among current and former smokers. He is co-PI of the Columbia Field Center of the MultiEthnic Study of Atherosclerosis, a 10-year prospective cohort study funded by NHLBI, PI of Mesa-Lung, a large study of endothelial function and lung function in that cohort, and PI at Columbia Mesa-Air, a 10-year prospective study on the health effects of air pollution funded by the EPA.
Education & Training:

    DrPH, 2002, Harvard School of Public Health

    MPH, 2000, Harvard School of Public Health

    MD, 1994, McGill University

    BA, 1988, Duke University

Affiliation(s):

University Affiliations:

  • Division of General Medicine  

Additional Affiliations:

  • Member, American Thoracic Society
  • Member, American College of Physicians
Honors and Awards:
  • Robert Wood Johnson Generalist Physician Faculty Scholar, 2001
  • Irving Scholar Award, Irving Center for Clinical Research, 2004
Selected
New York City
Activities:
    Poverty and Tuberculosis
    Dr. Barr analyzed neighborhood poverty and the resurgence of tuberculosis that New York City experienced from 1984 to 1992.

    Pesticide Spraying for West Nile Virus and Asthma
    Dr. Barr investigated the spraying of pesticide for West Nile Virus control and emergency department asthma visits in New York City.

Selected
Global
Activities:
    Economic Analysis of Tuberculosis Control
    Dr. Barr evaluated the cost effectiveness of scaled-up intensive (directly observed therapy) treatment for tuberculosis in 3 developing countries on medical and economic costs in those countries and in the U.S. and Canada.